Allergy Therapeutics (AGY)

 

AGY Share PerformanceMore

52 week high28.50 17/10/16
52 week low17.25 26/09/16
52 week change -1.27 (-4.80%)
4 week volume6,606,868 29/12/16

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Hardman Research: Investment driving market share

RNS Number: 6686U Allergy Therapeutics PLC 20 January 2017 Hardman Research: Investment driving market share gains Investment driving market share gains: AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in Europe only on a 'Named Patient' basis...

Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLC

finnCap today reaffirms its buy investment rating on Allergy Therapeutics PLC (LON:AGY) and raised its price target to ...

Allergy Therapeutics revenues up

Allergy Therapeutics expects reported revenues for the six months ended 31 December to be 40.4m - representing 17.9% orga...

Trading Update

RNS Number: 5437U Allergy Therapeutics PLC 19 January 2017 19 January 2017 Al l e r g y Th e r a p e u ti cs p l c (" A l l e r gy T he r a peu t i cs" or t he " C o m p a n y " ) Trading Update - H1 reported revenues ahead of expectations - Regulatory update: Pollinex Quattro clinical development programs to proceed as planned Allergy Therapeutics (AIM:AGY) , the f...

Top 10 small-cap share tips for 2017

AIM has outperformed all the other major domestic indices since Trump won the US election. Now, Harriet Mann reveals...

Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLC

finnCap today initiates coverage of Allergy Therapeutics PLC (LON:AGY) with a buy investment rating and price target o...

Grant of Awards

RNS Number: 1108T Allergy Therapeutics PLC 30 December 2016 30 December 2016 Al l e r g y Th e r a p e u ti cs p l c (" A l l e r gy T he r a peu t i cs" or t he ' C o m p a n y " ) Grant of Awards under Long Term Incentive Plan Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that, pursuant t...

Allergy Therapeutics resolutions passed at AGM

Allergy Therapeutics has confirmed that all resolutions proposed at its annual general meeting were passed. At 8:58am: (LO...

Fundamental DataMore

EPS-2.29
Dividend yield0 %

Equity Research (AGY)

Allergy Therapeutics plc
15/11/2016
InnovaDerma* (IDP.L) 107.5p £10.98m Strong news flow this week from the main market listed  UK developer of 'at-home' and clinically proven treatments for hair loss, hair care, self-...
hardman & co
Allergy Therapeutics plc
26/09/2016
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in Europe only on a ‘Named...
hardman & co
Allergy Therapeutics plc
07/06/2016
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. It’s lead product, Pollinex Quattro is available in Europe only on a ‘Named Patient’ basis. However,...

Latest discussion posts More

  • Zeus Capital - Director interview

    With thanks to another board. http://bit.ly/2khIXYV
    24-Jan-2017
    Baffler
  • Re: Detailed Report from Hardman - USA l...

    I agree and I stand corrected. Reading the latest missive from Hardman it seems that we have eighteen months of cash left to run. It would appear to me that it is imperative ...
    20-Jan-2017
    Baffler
  • Re: Detailed Report from Hardman - USA launc...

    I dont think you can really call it a "launch" - its a trial. AGY have been battling to get new trials approved by the FDA for several years after the first being blocked a ...
    20-Jan-2017
    Baker2005

Users' HoldingsMore

Users who hold Allergy Therapeutics also hold..
LLOYDS GRP.26%
BP17%
BARCLAYS15%
VODAFONE GRP.14%
NATIONAL GRID14%

Codes & Symbols

ISINGB00B02LCQ05
SymbolsAGY, LSE:AGY, AGY.L, AGY:LN, LON:AGY, XLON:AGY